Subclinical Cushing's Syndrome and Metabolic Disorder

Ji Cheol Bae

doi:10.3803/EnM.2014.29.4.441

Articles

Page Path: HOME > Endocrinol Metab > Volume 29(4); 2014 > Article

Editorial Subclinical Cushing's Syndrome and Metabolic Disorder: Ji Cheol Bae; Endocrinology and Metabolism 2014;29(4):441-442.
DOI: https://doi.org/10.3803/EnM.2014.29.4.441
Published online: December 29, 2014

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

Corresponding author: Ji Cheol Bae. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158 Paryong-ro, Masanhoewon-gu, Changwon 630-723, Korea. Tel: +82-55-290-1054, Fax: +82-55-290-1014, drkuri10@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2,763 Views
32 Download

Full Article

Download PDF

Article information
References

The concept of subclinical Cushing's syndrome stands on the presence of adrenocorticotropic hormone-independent subclinical hypercortisolism without a clear Cushingoid phenotype and may be observed in patients with an incidentally found adrenal adenoma [1]. Kim et al. [2] found that the prevalence of subclinical Cushing's syndrome in Korean patients with adrenal incidentaloma was 7.1% (19 of 268 patients), which suggests that subclinical hypercortisolism is commonly found in patients with this disorder. Moreover, the presence of subclinical hypercortisolism in these patients was also associated with an increased prevalence of cardiovascular disease risk factors such as diabetes and hypertension [2]. As findings shown in Kim's study, subclinical hypercortisolism is the most common hormonal abnormality in patients with adrenal incidentaloma [3] and even a very low excess of cortisol in patients with subclinical Cushing's syndrome may contribute to the development of metabolic disorders such as obesity, diabetes, hypertension, and osteoporosis [1,4]. Thus, there has been a recent rise in interest regarding the diagnosis and management of subclinical Cushing's syndrome.

A recent study by Di Dalmazi et al. [5] observed that the incidences of cardiovascular events and mortality were higher in patients with subclinical Cushing's syndrome compared to those with non-secreting adrenal incidentalomas over a mean follow-up period of 7.5 years. These authors suggested that this difference might be attributable to the relationship between subclinical cortisol excess and cardiovascular disease risk factors. The finding that subclinical hypercortisolism can harm patients implies that the management of subclinical Cushing's syndrome would be a beneficial strategy to mitigate the effects of this disease. However, there is insufficient evidence to conclude which management strategy may be most effective [1]. To date, the majority of studies investigating this issue have been conducted using retrospective and cross-sectional designs with small sample sizes and a variety of definitions. Only one prospective study has been published showing that laparoscopic adrenalectomy is more beneficial than conservative management for the improvement of cardiovascular disease risk factors [6].

Thus, it is necessary to conduct a high-quality prospective study of the long-term outcomes of patients with subclinical Cushing's syndrome, including their natural histories and the impending complications and/or risk factors. Furthermore, prospective studies should evaluate the effects of different management strategies on cardiovascular disease events and mortality in patients with adrenal incidentaloma and subclinical Cushing's syndrome [1,6]. Currently, a multicenter, randomized, controlled prospective study assessing the long-term metabolic effects of adrenalectomy in Korean patients with adrenal incidentalomas and subclinical Cushing's syndrome is underway (Clinicaltrial.gov: NCT01383420). The findings of this study will provide further insight into the effects of the management of subclinical Cushing's syndrome on metabolic disorders.

Article information

No potential conflict of interest relevant to this article was reported.

References

1. Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: definition and management. Clin Endocrinol (Oxf) 2012;76:12–18. Article PubMed
2. Kim BY, Chun AR, Kim KJ, Jung CH, Kang SK, Mok JO, Kim CH. Clinical characteristics and metabolic features of patients with adrenal incidentalomas with or without subclinical Cushing's syndrome. Endocrinol Metab 2014;29:457–463.Article
3. Anagnostis P, Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG, Mikhailidis DP. Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) 2009;8:163–184. Article PubMed
4. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011;96:1223–1236. Article PubMed
5. Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, Mosconi C, Golfieri R, Paccapelo A, Pagotto U, Pasquali R. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014;2:396–405. Article PubMed
6. Anagnostis P, Karras SN, Athyros VG, Mikhailidis DP, Karagiannis A. Subclinical Cushing's syndrome and cardiovascular disease. Lancet Diabetes Endocrinol 2014;2:361Article

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
Cite

CITE

export Copy Format

Close

XML Download